Methods and compositions for treating a subject with 15-hydroxyprostaglandin dehydrogenase inhibitors
EP4761729A1Pending Publication Date: 2026-06-24EPIRIUM BIO INC
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- EP2024857112
- Authority / Receiving Office
- EP · EP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-08-18
- Filing Date
- 2024-08-16
- Publication Date
- 2026-06-24
AI Technical Summary
Technical Problem
There is an unmet need for compositions and methods to reduce levels of biomarkers associated with diseases or conditions, such as p75ECD and PGE-MUM, in subjects.
Method used
The use of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) inhibitors to administer effective amounts to subjects, thereby reducing levels of p75ECD, PGE-MUM, or both, in these subjects.
Benefits of technology
The administration of 15-PGDH inhibitors effectively reduces the levels of biomarkers like p75ECD and PGE-MUM, potentially treating associated diseases or conditions.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure US2024042816_27022025_PF_FP_ABST
Abstract
Provided herein are compositions and methods for reducing levels of at least one biomarker in a subject. The at least one biomarker may include p75ECD, PGE-MUM, or both. In some cases, the compositions and methods provided herein involve administering to a subject an amount of a 15-hydroxyprostaglandin dehydrogenase (15-PGDH) inhibitor effective to reduce levels of the at least one biomarker in the subject.
Need to check novelty before this filing date? Find Prior Art